When was Prevail Therapeutics founded?

Prevail Therapeutics was founded in 2017 and raised its 1st funding round within a year of its incorporation.

Where is Prevail Therapeutics located?

Prevail Therapeutics is headquartered in New York City, United States.

Who is the current CEO of Prevail Therapeutics?

Asa Abeliovich of Prevail Therapeutics. They have also founded 2 companies.

How many employees does Prevail Therapeutics have?

As of Apr 30, 2026, the latest employee count at Prevail Therapeutics is 17.

Is Prevail Therapeutics a funded company?

Prevail Therapeutics is a funded company, having raised a total of $125M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2017.

When was the latest funding round of Prevail Therapeutics?

Prevail Therapeutics' latest funding was a $***** Series B round on Mar 27, 2019, with participation from 12 investors. Its primary sector is Genomics. In United States, the Genomics sector has seen $522M in funding in 2026 to date.

Where does Prevail Therapeutics rank among its competitors?

Prevail Therapeutics ranks 194th amongst 987 active competitors, of which 349 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Prevail Therapeutics?

Prevail Therapeutics' top competitors include Alnylam, Spark Therapeutics and Denali Therapeutics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Prevail Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of gene therapies for treating neurodegenerative and rare diseases. The company develops gene therapies targeting the genetic root causes of neurodegenerative and rare diseases, such as Parkinson's, frontotemporal dementia (FTD), and Gaucher disease. The company's product of the company, PR001 is an AAV-based gene therapy, which is targeting lysosomal dysfunction of the cell.

Website: prevailtherapeutics.com
Email ID: *****@prevailtherapeutics.com

Key Metrics

Founded Year

2017

Location

New York City, United States

Stage

Acquired

Total Funding

$125M in 3 rounds

Latest Funding Round

Series B, Mar 27, 2019, $*****

Investors

Orbimed & 13 more

Ranked

194^th among 987 active competitors

Employee Count

17 as on Apr 30, 2026

Similar Companies

Alnylam & 1245 more

Exit Details

Acquired by Lilly (Dec 15, 2020)

View Prevail Therapeutics' full profile

Prevail Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
PREVAIL THERAPEUTICS INC. CIN: 1714798 , United States, Active		-	-	-

Prevail Therapeutics got acquired by Lilly on Dec 15, 2020.

Click here to take a look at Prevail Therapeutics's acquisition in detail

Prevail Therapeutics has raised a total funding of $125M over 3 rounds. Its first funding round was on 2017. Its latest funding round was a Series B round on Mar 27, 2019 for $*****. 12 investors participated in its latest round. Prevail Therapeutics has 14 institutional investors.

Here is the list of recent funding rounds of Prevail Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 27, 2019	3406361	Series B	4185865	9754058	5692558	1501564
Mar 08, 2018	8387827	Series A	7276491	1008645	2064061	Orbimed & 1 more
2017	6932	Seed	2664	6750	Orbimed & 1 more	4377

Access funding benchmarks and valuations. Sign up today!

View details of Prevail Therapeutics's funding rounds and investors

The founders of Prevail Therapeutics is Asa Abeliovich. Asa Abeliovich is the CEO of Prevail Therapeutics.

Here are the details of Prevail Therapeutics' key team members:

Asa Abeliovich: Founder & CEO of Prevail Therapeutics and founder of 2 other companies, Leal Therapeutics and Alector.
Contact Info: 1 email address

View details of Prevail Therapeutics's Founder profiles and Board Members

Prevail Therapeutics' employee count trend

Prevail Therapeutics has 17 employees as of Apr 26. Here is Prevail Therapeutics's employee count trend over the years:

Employee count trend for Prevail Therapeutics

Uncover Prevail Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Prevail Therapeutics include Alnylam, Spark Therapeutics and Denali Therapeutics. Here is the list of Top 10 competitors of Prevail Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Bellevue Healthcare Trust ... & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	72/100
4th	Fulcrum Therapeutics 2015, Cambridge (United States), Public	Developing small molecules for control mechanisms and genes regulation for the treatment of rare diseases	$115M	Foresite Capital, Google Ventures & 15 others	71/100
5th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, MassChallenge & 19 others	70/100
6th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	Andreessen Horowitz, Foresite Capital & 18 others	70/100
7th	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
8th	Orchard Therapeutics 2015, London (United Kingdom), Acquired	Developer of gene therapies for treating rare diseases	$440M	Baillie Gifford, ORI Capital & 30 others	70/100
9th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
10th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	Healthcap, F-Prime Capital & 10 others	69/100
194th	Prevail Therapeutics 2017, New York City (United States), Acquired	Developer of gene therapies for treating neurodegenerative and rare diseases	$125M	Boxer Capital, BVF Partners & 12 others	51/100